Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CMB305 |
Synonyms | |
Therapy Description |
CMB305 is a combination of LV305, a dendritic cell-targeted lentiviral vector encoding NY-ESO-1, and G305, an NY-ESO-1 cancer vaccine, which may synergize to promote anti-tumor immunity (PMID: 29280411). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CMB305 | ID-CMB305|CMB 305 | CMB305 is a combination of LV305, a dendritic cell-targeted lentiviral vector encoding NY-ESO-1, and G305, an NY-ESO-1 cancer vaccine, which may synergize to promote anti-tumor immunity (PMID: 29280411). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03520959 | Phase III | CMB305 | Synovate Study for Synovial Sarcoma, Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma | Terminated | USA | CAN | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |